22 May 2013
Keywords: Agenus, Oncophage, Antigenics, ChemRar, NewVac
Article | 20 December 2011
US biotech firm Agenus (Nasdaq: AGEN), known as Antigenics until January of this year, has entered into a license, development ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 December 2011
© 2013 thepharmaletter.com